Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Leukemia. 2019 Jul 29;33(12):2971–2974. doi: 10.1038/s41375-019-0529-2

Figure 2. ROC-325 augments the anti-leukemic activity of azacitidine to significantly extend survival.

Figure 2.

(a) ROC-325 cooperates with azacitidine to diminish the viability of AML cells. MOLM-13, MV4–11, HL-60 and KG-1 cells were treated with 1 μM ROC-325, 1 μM azacitidine, or the combination for 72 h. Cell viability was determined by MTT assay. N = 3 ± SD. (b) ROC-325 and azacitidine significantly extend survival. MV4–11 cells (1 × 106 per mouse) were injected into the tail veins of NOD/SCID mice (N = 10 per group) to establish a disseminated xenograft model of AML. Mice were treated with vehicle control, 50 mg/kg PO QD ROC-325, 5 mg/kg azacitidine IV Q3D, or both drugs. The survival benefit of each treatment was determined by Kaplan-Meier analysis. (c) ROC-325 inhibits autophagy in vivo. Bone marrow and spleen specimens were collected from mice in each treatment group at study endpoint and levels of LC3B and p62 were measured by immunohistochemistry.